Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Safety and efficacy of DES in saphenous vein bypass graft PCI

Original title: Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: insights from the Veterans Affairs CART program. Reference: Aggarwal V et al. J Am Coll Cardiol. 2014;64:1825-1836.

 

This study retrospectively evaluated 2471 receiving after saphenous vein graft (SVG) PCI between October and September 2011. Outcomes were compared using propensity score matching between 895 patients treated with conventional bare metal stents (BMS) and 901 patients treated with drug eluting stents (DES).

The use of DES compared to BMS increased from 50% in 2008 to 69% in 2011. Peri procedural complications were low for both groups (2.8% with BMS vs 2.3% with DES; p=0 .54) but the long term showed differences.

At median follow up of 2.8 years, the use of DES was associated with lower mortality rates after propensity score matching (HR 0.72; CI 95% 0.57 to 0.89). Despite the difference in mortality, infarction rate was similar in both groups and these results were no different when looking at the different DES patients received. 

Conclusion

In this great cohort, increasing use of DES during SVG PCI was observed, compared to the use of BMS. Long term follow up showed DES were safe and effective. 

Editorial Comment

In the absence of a randomized study to confirm these data, the lower mortality rate observed with the use of DES in this study should be interpreted with caution, since it cannot be explained by a lower infarction rate.

Another limitation to this study is the lack of information on restenosis and revascularization, where we should see a greater advantage of DES.

SOLACI

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...